Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Micic

Showing results (51-60 of 53) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 53 results.
Endocrine Pathology|May 3, 2020
Elevated adrenocorticotropic hormone and cortisol levels in a patient with medullary carcinoma of the thyroid containing ectopic immunoreactive corticotropin-releasing hormone and bombesinV Popovic, Z Milosevic, I Doniach, et al.
Acta Paediatrica (Oslo, Norway : 1992). Supplement|December 24, 1997
Growth hormone secretagogues in pathological states: diagnostic implicationsV Popovic, D Micic, S Damjanovic, et al.
Alimentary Pharmacology & Therapeutics|January 30, 2018
Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel diseaseB Christensen, D Micic, P R Gibson, et al.
Pageof 6

Showing results (51-60 of 53) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 53 results.
Endocrine Pathology|May 3, 2020
Elevated adrenocorticotropic hormone and cortisol levels in a patient with medullary carcinoma of the thyroid containing ectopic immunoreactive corticotropin-releasing hormone and bombesinV Popovic, Z Milosevic, I Doniach, et al.
Acta Paediatrica (Oslo, Norway : 1992). Supplement|December 24, 1997
Growth hormone secretagogues in pathological states: diagnostic implicationsV Popovic, D Micic, S Damjanovic, et al.
Alimentary Pharmacology & Therapeutics|January 30, 2018
Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel diseaseB Christensen, D Micic, P R Gibson, et al.
Pageof 6